|
MechanismGABAA receptor agonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date04 Jun 1975 |
口服盐酸埃他卡林片人体药代动力学和进食影响及E-QT研究的补充试验
[Translation] Oral Pharmacokinetics and Feeding Effects of Etacaline Hydrochloride Tablets and Supplementary Trial of E-QT Study
在健康受试者中进行单剂、连续口服盐酸埃他卡林片的药代动力学研究补充试验及进食对单剂口服盐酸埃他卡林片(10mg)药代动力学的影响,并通过建立药物暴露量与QT间期量效关系模型,初步预测盐酸埃他卡林片在中国健康受试者中是否对QT间期延长有影响。
[Translation] Pharmacokinetic study of single-dose, continuous oral Etacaline Hydrochloride Tablets in healthy subjects and the effect of food intake on the pharmacokinetics of single-dose oral Etacaline Hydrochloride Tablets (10mg) were conducted in a supplementary test and evaluated by A dose-response relationship model between drug exposure and QT interval was established to preliminarily predict whether etacalin hydrochloride tablets have an effect on QT interval prolongation in Chinese healthy subjects.
100 Clinical Results associated with Jiangsu Nhwa-Sede Pharm Co Ltd
0 Patents (Medical) associated with Jiangsu Nhwa-Sede Pharm Co Ltd
100 Deals associated with Jiangsu Nhwa-Sede Pharm Co Ltd
100 Translational Medicine associated with Jiangsu Nhwa-Sede Pharm Co Ltd